Trident Lifeline Ltd

Trident Lifeline Ltd has announced a Board of Directors meeting scheduled for October 26, 2026. The primary agenda items include the consideration and approval of the Unaudited Financial Results (Standalone & Consolidated) for the half-year ended September 30, 2026. Additionally, the board will discuss the declaration of a first interim dividend for the Financial Year 2026-27, if applicable. The trading window for the company's equity shares, which was closed from October 1, 2026, will reopen 48 hours after the results are made public.

Trident Lifeline Ltd has allotted 24,000 equity shares of face value Rs. 10 each at an issue price of Rs. 266 per share (including a premium of Rs. 256) upon conversion of an equal number of warrants. The company received Rs. 47,88,000 for this conversion, representing 75% of the issue price per warrant. This allotment increases the company's issued, subscribed, and paid-up equity share capital to Rs. 11,98,10,000, comprising 11,981,000 equity shares. The new shares rank pari-passu with existing equity shares. The conversion was executed by one warrant holder, Vishal Bhupendra Halvawala, who still has 24,000 warrants pending for conversion.

Trident Lifeline Ltd has allotted 24,000 equity shares following the conversion of an equal number of warrants. The conversion was executed upon receipt of the remaining 75% of the issue price from warrant holders. The total amount received for this conversion was Rs. 47,88,000. This allotment increases the company's issued, subscribed, and paid-up equity share capital to Rs. 11,98,10,000, comprising 11,981,000 equity shares of Rs. 10/- each. The new shares will rank pari-passu with existing equity shares.

Trident Lifeline Limited has issued a corrigendum to its Extra-ordinary General Meeting (EOGM) Notice originally dated October 5, 2026. The EOGM is scheduled for October 27, 2026, to be held via Video Conferencing. The corrigendum addresses observations from BSE regarding a proposed preferential issue of equity shares and convertible warrants. It also rectifies inadvertently incorrect Ultimate Beneficial Owner (UBO) details for one of the proposed allottees, FINCOS TECHNOLOGY SOLUTIONS PRIVATE LIMITED. The changes are made in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and other applicable laws. Shareholders are requested to note these updates, which will be available on the company's and BSE's websites.

Trident Lifeline Ltd's Board of Directors met on October 16, 2026, to approve a preferential issue of 12,22,200 Equity Shares and 5,00,400 Warrants. The funds raised will be utilized for working capital requirements (₹4,211.97 Lacs / ₹42.12 Crore), investments in subsidiaries/associates/joint ventures (₹2,056.96 Lacs / ₹20.57 Crore), and business expansion/general corporate purposes (₹1,028.97 Lacs / ₹10.29 Crore). The board also approved issuing a corrigendum to the EGM notice to shareholders reflecting these changes.

Trident Lifeline Ltd announced that its subsidiary, Trident Mediquip Limited (TML), has completed a private placement of equity shares. Following this placement, Trident Lifeline's shareholding in TML has decreased from 59.67% to 58.23%. TML operates in the Medical Device Industry and reported a turnover of ₹27.31 Cr for FY26. The transaction is considered a related party transaction as TML is a subsidiary, but it is being conducted on an arm's length basis. No specific acquisition cost or consideration details were provided as the transaction relates to a subsidiary's internal share allotment.

Trident Lifeline Limited participated in CPHI Milan 2026, a significant event for showcasing its healthcare product portfolio and exploring opportunities in regulated pharmaceutical markets. The company aimed to build visibility, gain entry into high-bar regulatory geographies, and secure international exposure. The event facilitated organic customer interactions, leading to valuable leads and actionable market intelligence on shifting global pharma trends. Trident Lifeline, a pharmaceutical and healthcare company, offers a diversified portfolio and focuses on quality-led healthcare solutions across domestic and international markets.

Trident Lifeline Ltd has issued a clarification regarding a typographical error in its previous Board Meeting outcome submission dated October 5, 2026. The correction pertains to specific names mentioned in Annexure-I of the outcome document. The company confirms that all other details and terms approved by the Board remain unchanged, emphasizing the error was purely clerical and unintentional. The revised outcome has been submitted for record.

Trident Lifeline Ltd will hold an Extra-Ordinary General Meeting (EGM) on Tuesday, October 27, 2026, at 04:00 p.m. (IST) via Video Conferencing/Other Audio Visual Means. The EGM will consider and approve two special resolutions: first, to alter the Article of Association to empower the Board to issue or reissue bonds, debentures, or other securities convertible into equity shares, subject to member sanction for conversion rights; and second, to approve the issuance of equity shares to proposed allottees on a preferential basis. Remote e-voting facilities will be available for shareholders from October 24, 2026, to October 26, 2026, with October 20, 2026, as the cut-off date.

Trident Lifeline Ltd's Board of Directors has approved a preferential issue of 12,22,200 equity shares and up to 5,00,400 warrants. The equity shares will be issued at ₹336.60 each, aggregating ₹41.14 Crore. The warrants, also at ₹336.60 each, are convertible into equity shares and can raise up to ₹16.84 Crore. This is subject to shareholder approval at an Extra-Ordinary General Meeting (EGM) scheduled for October 27, 2026. The Board also approved altering the Article of Association to facilitate the issuance of warrants. NSDL has been appointed as the Remote E-Voting Agency for the EGM.